Study to evaluate osteoarthritis and nociceptive pain by measuring microRNA in blood samples

Not Applicable

• Conditions: Osteoarthritis

• Registration Number: JPRN-UMIN000052943
• Lead Sponsor: Kawasaki Medical School

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-01-01
• Last Update Posted: 27 May 2024
• Study Completion: 2027-03-31

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 180

Inclusion Criteria

Not provided

Exclusion Criteria

OA group Exclusion criteria 1) Patients with severe pain in a location other than the hip joint (bilateral hip osteoarthritis is not excluded) 2) Patients with severe cognitive dysfunction (delirium, dementia, mental retardation, or other mental decline) at the time of preintervention evaluation. 3) Patients who have difficulty in communicating, reading, and writing in Japanese 4) Other subjects deemed inappropriate for this study by the principal investigator Fracture group Exclusion criteria 1) Patients with preoperative severe osteoarthritis of the hip joint 2) Patients with severe cognitive dysfunction (delirium, dementia, mental retardation, or other mental decline) at the time of preintervention evaluation 3) Patients who have difficulty in communicating, reading, and writing in Japanese. 4) Other subjects deemed inappropriate for this study by the principal investigator Normal group Exclusion Criteria 1) Patients with illnesses requiring immediate medical treatment 2) Persons with a history of alcohol or drug abuse or those who admit it at this time 3) Persons with a history of manic or psychotic states, or those who admit it at present 4) Persons who have or currently admit to having significant feelings of hopelessness 5) Those with strong cognitive impairment. 6) Those who have difficulty in communicating, reading, and writing in Japanese. 7) Others who the principal investigator deems inappropriate to participate in the research.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Expression levels of miRNAs in OA patients and healthy subjects